FX.co ★ Absci Announces Strategic Collaboration With AMD To Advance AI-Driven Drug Discovery

Absci Corporation (ABSI), a biotech firm headquartered in Washington, has recently unveiled a strategic partnership with AMD. This collaboration aims to leverage AMD Instinct accelerators along with ROCm software to enhance AI-driven tasks pivotal for drug discovery, notably Absci's sophisticated de novo antibody design models. Additionally, AMD is set to make a $20 million investment in Absci via a Private Investment in Public Equity (PIPE), underscoring the growing interest in innovative AI applications in the pharmaceutical research sector. Currently, ABSI shares are trading at $3.28, marking a 6.84% increase on the Nasdaq Global Select Market.